| P50 | author | Derek R. Johnson | Q39619810 |
| | Martin J van den Bent | Q61372103 |
| | Marjolein Geurts | Q90813304 |
| | Jan C Buckner | Q92446222 |
| P2093 | author name string | Michael W Ruff | |
| P2860 | cites work | Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 |
| | Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. | Q30275188 |
| | International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors | Q30426724 |
| | Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | Q30542081 |
| | Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. | Q30807440 |
| | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome | Q31113299 |
| | Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. | Q33186142 |
| | 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. | Q33254265 |
| | Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group | Q34059674 |
| | Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 |
| | Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. | Q34446549 |
| | Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. | Q36898973 |
| | Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma | Q37518265 |
| | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide | Q38390616 |
| | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study | Q38816272 |
| | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 |
| | Penetration of intra-arterially administered vincristine in experimental brain tumor | Q42243011 |
| | NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 |
| | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study | Q48157598 |
| | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. | Q48295109 |
| | Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas | Q48374829 |
| | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study | Q48428672 |
| | Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial | Q48467310 |
| | Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. | Q48493738 |
| P433 | issue | 1 | |
| P921 | main subject | temozolomide | Q425088 |
| | oligodendroglioma | Q1318384 |
| | adult oligodendroglioma | Q18555324 |
| P304 | page(s) | 17-21 | |
| P577 | publication date | 2018-11-03 | |
| P1433 | published in | Neuro-oncology practice | Q27726109 |
| P1476 | title | Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma | |
| P478 | volume | 6 | |